Can Dasatinib Overcome the Negative Effects of KIT Mutations in Core Binding Factor AML?
A chemotherapy regimen of cytarabine and daunorubicin plus dasatinib was well tolerated in patients with previously untreated core binding factor acute myeloid leukemia (CBF-AML)...
Metabolic Syndrome Predicts Risk of Recurrent VTE in Patients With Newly Diagnosed DVT
Patients with newly diagnosed deep vein thrombosis (DVT) who have components of metabolic syndrome – hypertension, hyperlipidemia, diabetes mellitus, or obesity – have a...
FDA Grants Breakthrough Designation to APR-246 for MDS
The FDA granted breakthrough therapy designation to APR-246 in combination with azacitidine for the treatment of patients with myelodysplastic syndromes (MDS) and a TP53...
FDA Asks Manufacturer to Withdraw Diet Drug Over Cancer Risk
The FDA issued a safety communication asking Eisai Co. to voluntarily recall its weight management drug lorcaserin, a selective activator of 5-HT2C serotonin receptors...
Higher Altitudes, Higher Hemoglobin: Mapping Switzerland’s Topography and Hemoglobin Levels
Even small increases in residential altitude significantly elevated blood hemoglobin (Hb) and ferritin levels in young men living in Switzerland, according to a study...
Germline RUNX1 Mutations in RUNX1-Mutated AML More Frequent Than Previously Thought
A small study in Canada shows that the frequency of germline RUNX1 mutations in patients with RUNX1-mutated acute myeloid leukemia (AML) is higher than...
Patients With SCD and TP53 Mutations May Develop Myeloid Malignancy After Unsuccessful AlloHCT
Population studies have shown that patients with sickle cell disease (SCD) who have undergone an unsuccessful allogeneic hematopoietic cell transplantation (alloHCT) have an increased...
Remembering Clara Bloomfield, City of Hope Appoints Eileen Smith as Head of Hematology, and...
Remembering Clara Bloomfield, MD (1942 – 2020)
Leukemia scientist Clara Bloomfield, MD, died on March 1, 2020 at the age of 77.With more than 50...
Hemophilia A Gene Therapy Offers Sustained Clinical Benefit
In men with severe hemophilia A, treatment with an adeno-associated virus serotype 5 (AAV5) vector containing a B-domain-deleted factor VIII (FVIII) gene, known as...
Tazemetostat Granted Priority Review for Relapsed/Refractory Follicular Lymphoma
The FDA granted a priority review to the new drug application (NDA) for tazemetostat for the treatment of patients with relapsed or refractory follicular...
Current Issue
April 2020, Volume 6, Issue 5
This issue examines current immunization guidelines for patients with hematologic disorders, considers medical education amid the coronavirus pandemic, and more.
